TNFRSF17 and Miyoshi myopathy: Furthermore, in a phase 1 study of relapsed/refractory MM patients (n = 6 assessable patients), treatment with the γ-secretase inhibitor JSMD194 in combination with anti-BCMA CAR T cell therapy led to an ORR of 100% (5 VGPR, 1 PR)42.